Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-05-01
2011-10-11
Sang, Hong (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300
Reexamination Certificate
active
08034902
ABSTRACT:
The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5910573 (1999-06-01), Pluckthun et al.
patent: 2003/0219434 (2003-11-01), Carter et al.
patent: 2006/0134110 (2006-06-01), Durrant
patent: 125023 (1984-11-01), None
patent: 171496 (1986-02-01), None
patent: 173494 (1986-03-01), None
patent: 184187 (1986-06-01), None
patent: 0552142 (1991-02-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 96/13583 (1996-05-01), None
patent: WO 96/37621 (1996-11-01), None
patent: WO 97/02671 (1997-01-01), None
patent: WO 97/32021 (1997-09-01), None
patent: WO 2004/048413 (2004-10-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Rudikoff, Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Colman, Research in Immunology, 145:33-36, 1994.
Bendig, Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.
MacCallum et al, J. Mol. Biol., 262, 732-745, 1996.
Casset et al, Biochemical and Biophysical Research Communications, 307:198-205, 2003.
U.S. Appl. No. 08/256,790, filed Jul. 22, 1994, Pluckthun, et al.
M Better, CP Chang, RR Robinson, and Ah Horwitz Escherichia coli secretion of an active chimeric antibody fragment Science May 20, 1988: 1041-1043.
Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature. Dec. 13-19, 1984;312(5995):643-6.
Byers VS, Pimm MV, Scannon PJ, Pawluczyk I, Baldwin RW. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.Cancer Res 1987. 47: 5042-5046.
Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH, Baldwin RW, Scannon PJ.Phase I study of monoclonal antibody-ricin a chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.1989, Cancer Res 49: 6153-6160.
Cabilly S, Riggs AD, Pande H, Shively JE, Holmes WE, Rey M, Perry L.J, Wetzel R, Heyneker HL.Generation of antibody activity from immunoglobulin polypeptide chains produced inEscherichia coli. Proc Natl Acad Sci U S A. Jun. 1984;81(11):3273-7.
Di Gaetano N, Cittera E, Nota R, Vecchi a, Grieco V, Scanziani E, Botto M, Introna M, Golay J.Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. Aug. 1, 2003;171(3):1581-7.
Gavilondo JV, Larrick JW. Antibody engineering at the millennium. Biotechniques. Jul. 2000;29(1):128-32, 134-6, 138 passim.
Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. Mar. 2004;25(3):158-64.
Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. Jun. 15, 2000;95(12):3900-8.
Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. Dec. 1, 2001;98(12):3383-9.
Hakulinen J, Meri S. Complement-mediated killing of microtumors in vitro. Am J Pathol. Sep. 1998;153(3):845-55.
Hanke T, Szawlowski P, Randall RE. Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol. Mar. 1992;73 ( Pt 3):653-60.
Ed Harlow and David Lane “Antibodies; A Laboratory Manual” from Cold Spring Harbor Laboratory press, Dec. 1, 1988; pp. 139-149.
Hekman A, Honselaar A, Vuist WM, Sein JJ, Rodenhuis S, ten Bokkel Huinink WW, Somers R, Rümke P, Melief CJ. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother. 1991;32(6):364-72.
Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. Jul. 15, 1993;90(14):6444-8.
Liu AY, Robinson RR, Murray ED Jr, Ledbetter JA, Hellstrom I, Hellström KE. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol. Nov. 15, 1987;139(10):3521-6.
Karpovsky B, Titus JA, Stephany DA, Segal DM Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med. Dec. 1, 1984;160(6):1686-701.
E Li, A Pedraza, M Bestagno, S Mancardi, R Sanchez, and O Burrone Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng. 1997 10: 731-736.
Mack M, Riethmüller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A. Jul. 18, 1995;92(15):7021-5.
Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. Nov. 1, 2007;67(21):10556-63.
Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol. Oct. 2002;32(10):2773-82.
Milstein C, Cuello AC Hybrid hybridomas and their use in immunohistochemistry. Nature. Oct. 6-12, 1983;305(5934):537-40.
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. Nov. 1984;81(21):6851-5.
Neuberger MS, Williams GT, Fox RO. Recombinant antibodies possessing novel effector functions. Nature. Dec. 13-19, 1984;312(5995):604-8.
Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. Feb. 1987;69(2):584-91.
Ridgway, J.B., Presta, L.G., Carter, P., “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996. 9, 617.
Sahagan BG, Dorai H, Saltzgaber-Muller J, Toneguzzo F, Guindon CA, Lilly SP, McDonald KW, Morrissey DV, Stone BA, Davis GL, et al. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J Immunol. Aug. 1, 1986;137(3):1066-74.
Sblattero D, Bradbury A. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol. Jan. 2000;18(1):75-80.
Sblattero D, Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology. Jan. 1998;3(4):271-8.
Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2
eu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. Dec. 24, 2004;279(52):53907-14.)
Sun LK, Curtis P, Rakowicz-Szulczynska E, Ghrayeb J, Chang N, Morrison SL, Koprowsk
Marzari Roberto
Sblattero Daniele
Tedesco Francesco
Cooper & Dunham LLP
Quark Pharmaceuticals Inc.
Sang Hong
White John P.
LandOfFree
Recombinant antibodies against CD55 and CD59 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant antibodies against CD55 and CD59 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant antibodies against CD55 and CD59 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252789